IQI News and Press, Invesco Quality Municipal Income Trust From 03/02/24

2024-03-02 23:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-30 08:57:01 ET More on Invesco Quality Municipal Income Trust Dividend scorecard for Invesco Quality Municipal Income Trust Read the full article on Seeking Alpha For further details see: Invesco Quality Municipal Income Trust raises dividend by 12.6% to ...

2024-01-09 05:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-14 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-10-03 10:49:39 ET Invesco Quality Municipal Income Trust ( NYSE: IQI ) declares $0.0358/share monthly dividend . Forward yield 5.16% Payable Oct. 31; for shareholders of record Oct. 16; ex-div Oct. 13. See IQI Dividend Scorecard, Yield Chart, & Divid...

2023-09-02 04:30:33 ET More on Invesco Quality Municipal Income Trust Dividend scorecard for Invesco Quality Municipal Income Trust For further details see: Invesco Quality Municipal Income Trust cuts dividend by ~4%

(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley tells Proactive the company is preparing an application to gain key regulatory approval to begin clinical trials in the US for its psilocybin-assisted psychotherapy development program (Psi-GAD)...

(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive after the company received clearance from the US Food and Drug Administration (FDA) to begin the Phase 2/3 clinical trial for its IHL-42X asset, designed to address obstruc...

(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive the company has completed a constructive pre-Investigational New Drug (IND) application meeting with the US Food and Drug Administration (FDA) for its IHL-675A proprietary dr...

(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical trial investigating the company’s IHL-42X for the treatment of Obstructiv...